Waypoint Bio raises $20M series a

Waypoint Bio raised $20M in series a funding, announced on 1 June 2026, led by Amplify Partners, with participation from General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, Hummingbird Ventures. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.

AI-driven cell therapy startup developing in vivo CAR T therapeutics using spatial pooled screening and computer vision. Waypoint Bio is based in United States and currently at series a stage, operating in healthtech, deeptech, cell therapy.

Lux Capital is profiled on Raise, Fusion42's database of venture funds — where each investor's thesis, cheque size and other tracked backings can be followed. This funding event is a citable node in Fusion42's market graph: it links Waypoint Bio's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur, Fusion42's AI co-founder, reasons over when benchmarking a founder's own raise against what is closing in the market right now.

Round details

Explore: Series A · United States

Verified 1 June 2026 · Sources: public filings